300 related articles for article (PubMed ID: 17184594)
1. Design, synthesis, antitumor evaluations and molecular modeling studies of novel 3,5-substituted indolin-2-one derivatives.
Li HH; Zheng XH; Tan JZ; Chen LL; Liu H; Luo XM; Shen X; Lin LP; Chen KX; Ding J; Jiang HL
Acta Pharmacol Sin; 2007 Jan; 28(1):140-52. PubMed ID: 17184594
[TBL] [Abstract][Full Text] [Related]
2. [Synthesis of 1-furfuryl-indolin-2-one derivatives and preliminary evaluation of their antitumor activities].
Dong XC; Zhou FS; Zheng JB; Wen R
Yao Xue Xue Bao; 2008 Jan; 43(1):54-9. PubMed ID: 18357732
[TBL] [Abstract][Full Text] [Related]
3. Discovering novel 3-nitroquinolines as a new class of anticancer agents.
Li HH; Huang H; Zhang XH; Luo XM; Lin LP; Jiang HL; Ding J; Chen KX; Liu H
Acta Pharmacol Sin; 2008 Dec; 29(12):1529-38. PubMed ID: 19026174
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ
Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and antitumor evaluation of a new series of N-substituted-thiourea derivatives.
Li J; Tan JZ; Chen LL; Zhang J; Shen X; Mei CL; Fu LL; Lin LP; Ding J; Xiong B; Xiong XS; Liu H; Luo XM; Jiang HL
Acta Pharmacol Sin; 2006 Sep; 27(9):1259-71. PubMed ID: 16923349
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.
Sun L; Tran N; Tang F; App H; Hirth P; McMahon G; Tang C
J Med Chem; 1998 Jul; 41(14):2588-603. PubMed ID: 9651163
[TBL] [Abstract][Full Text] [Related]
7. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives.
Cho TP; Dong SY; Jun F; Hong FJ; Liang YJ; Lu X; Hua PJ; Li LY; Lei Z; Bing H; Ying Z; Qiong LF; Bei FB; Guang LL; Shen GA; Hong SG; Hong SW; Tai MX
J Med Chem; 2010 Nov; 53(22):8140-9. PubMed ID: 21028894
[TBL] [Abstract][Full Text] [Related]
8. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
9. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 2-indolinone derivatives as potential antitumor agents.
Zou H; Zhang L; Ouyang J; Giulianotti MA; Yu Y
Eur J Med Chem; 2011 Dec; 46(12):5970-7. PubMed ID: 22019188
[TBL] [Abstract][Full Text] [Related]
11. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
[TBL] [Abstract][Full Text] [Related]
12. Quinols as novel therapeutic agents. 2.(1) 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents.
Berry JM; Bradshaw TD; Fichtner I; Ren R; Schwalbe CH; Wells G; Chew EH; Stevens MF; Westwell AD
J Med Chem; 2005 Jan; 48(2):639-44. PubMed ID: 15658878
[TBL] [Abstract][Full Text] [Related]
13. DNA-based electrochemical biosensors for monitoring of bis-indoles as potential antitumoral agents, chemistry, X-ray crystallography.
Maciejewska D; Szpakowska I; Wolska I; Niemyjska M; Mascini M; Maj-Zurawska M
Bioelectrochemistry; 2006 Sep; 69(1):1-9. PubMed ID: 16307909
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and anticancer activity of Indolin-2-one derivatives bearing the 4-thiazolidinone moiety.
Wang S; Zhao Y; Zhu W; Liu Y; Guo K; Gong P
Arch Pharm (Weinheim); 2012 Jan; 345(1):73-80. PubMed ID: 21932254
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, antiproliferative activity, and structure-activity relationships of 3-aryl-1H-quinolin-4-ones.
Xiao ZP; Li HQ; Shi L; Lv PC; Song ZC; Zhu HL
ChemMedChem; 2008 Jul; 3(7):1077-82. PubMed ID: 18433075
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of novel 7-azaindazolyl-indolyl-maleimide derivatives as antitumor agents and protein kinase C inhibitors.
Ye Q; Cao J; Zhou X; Lv D; He Q; Yang B; Hu Y
Bioorg Med Chem; 2009 Jul; 17(13):4763-72. PubMed ID: 19447039
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase.
Abouzid K; Shouman S
Bioorg Med Chem; 2008 Aug; 16(16):7543-51. PubMed ID: 18678492
[TBL] [Abstract][Full Text] [Related]
18. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.
Sun L; Tran N; Liang C; Hubbard S; Tang F; Lipson K; Schreck R; Zhou Y; McMahon G; Tang C
J Med Chem; 2000 Jul; 43(14):2655-63. PubMed ID: 10893303
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and cytotoxicity of novel 3-amino-4-indolylmaleimide derivatives.
Zhao SY; Yang YW; Zhang HQ; Yue Y; Fan M
Arch Pharm Res; 2011 Apr; 34(4):519-26. PubMed ID: 21544716
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antiproliferative activities of indolin-2-one derivatives bearing amino acid moieties.
Sassatelli M; Debiton E; Aboab B; Prudhomme M; Moreau P
Eur J Med Chem; 2006 Jun; 41(6):709-16. PubMed ID: 16675065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
